Research area
Health & Longevity
Human health, disease, treatment and aging. The largest corpus area supports distinct cancer, neurological and therapeutic navigation.
-
Evidence date ·Could cancer treatment change the risk from COVID-19?
Review or Meta-AnalysisEarly data suggested checkpoint inhibitors might not worsen COVID-19 outcomes in people with cancer, but separating cancer's effects from treatment remained difficult.
-
Evidence date ·Why radiation research asks two questions about the gut microbiome
Review or Meta-AnalysisA 2021 review asks whether gut microbes affect tumor response and digestive injury during radiation therapy, noting a preclinical vancomycin finding.
-
Evidence date ·How could a tiny particle help deliver cancer immunotherapy and shape the immune response?
Review or Meta-AnalysisA 2021 review surveys how tiny engineered particles could deliver immune therapies and influence immune activity; it reports no new patient results.
-
Evidence date ·What did early trials reveal about engineered T cells for pancreatic and biliary cancers?
Review or Meta-AnalysisIn seven early CAR T trials, researchers tried different tumor targets and reported very few severe side effects. Whether patients benefited was still being studied.
-
Evidence date ·Some newer cancer drugs act against brain metastases. Can they work alone?
Review or Meta-AnalysisA 2021 review reports that several newer cancer drugs showed high activity against brain metastases. Whether they can replace local treatment remains unresolved.
-
Evidence date ·After immunotherapy, treatment choices remain difficult for some metastatic colorectal cancers
Review or Meta-AnalysisA 2021 review asks whether chemotherapy and antibody drugs help people with metastatic colorectal cancer and faulty DNA repair when immunotherapy does not work.
-
Evidence date ·A three-part treatment plan for people with inoperable stage III lung cancer
Clinical TrialTracked over timeDEDALUS proposes chemotherapy and immunotherapy first, then chest radiation with an immune-targeting drug for some people with stage III lung cancer. Its 2023 paper describes a study design, not patient results.
-
Evidence date ·Why is EA5181 testing durvalumab earlier in treatment?
Review or Meta-AnalysisTracked over timeEarlier trials reported 38%–46% local failure after chemoradiation. A 2022 review explains why EA5181 tests adding durvalumab during treatment.
-
Evidence date ·How lung inflammation rates varied in stage III lung cancer studies
Review or Meta-AnalysisTracked over timeIn a 13-study review, clinical trials reported grade 2 lung inflammation rates of 23% when immune therapy overlapped chemoradiation and 11% when it followed.
-
Evidence date ·Why did immunotherapy draw interest in advanced or treatment-resistant digestive cancers?
Review or Meta-AnalysisA 2021 review explains why directing immune activity toward tumor features seemed promising for digestive cancers that had spread or resisted initial treatment.